IGM Biosciences reports Q3 EPS ($1.04), consensus ($1.21)

Reports Q3 revenue $509,000, consensus $810,000. “During the third quarter, we continued to execute across our clinical development pipeline,” said Fred Schwarzer, CEO of IGM Biosciences. “We have significantly expanded the number of active sites for our aplitabart randomized study, including multiple international sites, begun our Phase 1b clinical trials of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis and received FDA clearance of our IND application to begin a third Phase 1b autoimmune clinical trial of imvotamab. Our progress in the clinical development of these pipeline product candidates reinforces our commitment to the broad development of our Death Receptor 5 agonist platform and our T cell engager platform for autoimmune diseases.”